Bristol-Myers Squibb Company (BMY) 50.36 $BMY
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - 33 mins ago
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Final Glance: Pharmaceuticals companies
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Will Bristol-Myers (BMY) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:45PM CDT
Bristol-Myers (BMY) is scheduled to release its first quarter 2014 results before the opening bell on Tuesday, Apr 29.
Midday Glance: Pharmaceuticals companies
AP - Mon Apr 28, 1:01PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
Early Glance: Pharmaceuticals companies
AP - Mon Apr 28, 9:56AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2014
M2 - Mon Apr 28, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b6657v/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - BioLineRx, Ltd. - Bayer AG - Alchemia Limited - Emisphere Technologies, Inc. - Merrion Pharmaceuticals Plc - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/b6657v/deep_vein
Global Alopecia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ckzc5/alopecia) has announced the addition of the "Global Alopecia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Alopecia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Co., Ltd. - AntiCancer, Inc. - Panacea Biotec Limited - ProCertus BioPharm Inc. - AndroScience Corporation - Hygeia Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lee's Pharmaceutical Holdings Limited - Berg Pharma, LLC - vida therapeutics inc. Drug Profiles - abatacept - ruxolitinib - CB-0301 - calcitriol - Small Molecule Antagonists To Transforming Growth Factor Beta Receptor For Alopecia, Pulmonary Fibrosis And Dermatology - ZK-003 - HYG-430 - HYG-420 - HYG-410 - ASCJ-9 - KI-1104 - Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - V-2248 - ProDermaCel - Lipo-4MA - KI-1105 - Drug to Agonize P2Y5-Ligand LPA for Alopecia - Drug For Autoimmune Disorders - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia - Peptide For Hair Regeneration For more information visit http://www.researchandmarkets.com/research/4ckzc5/alopecia
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - Mon Apr 28, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...
Hepatitis C Space Heats Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
What looked like a two-horse hepatitis C race between Gilead Sciences and AbbVie has gotten more interesting, with Merck and Bristol-Myers Squibb presenting data on their hepatitis C drugs at a scientific meeting earlier this month. ...
3 Questions About a Big Pharma Megamerger
Seth Robey, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
It's been hard to miss the action in Big Pharma this week, as some of the most established drug makers engaged in a series of acquisition, merger, and asset swap rumors. A buyout of English company AstraZeneca by American powerhouse Pfizer was...
Schedule for Upcoming Earnings Releases -- Research on Nokia, Boston Scientific, Merck & Co., and Bristol-Myers Squibb
PR Newswire - Fri Apr 25, 1:09PM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Nokia OYJ (NYSE: NOK), Boston Scientific Corp. (NYSE: BSX), Merck & Co. Inc. (NYSE: MRK) and Bristol-Myers Squibb Co. (NYSE: BMY). Full earnings notes on NOK, BSX, MRK and BMY can be downloaded upon signing up at:
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - 33 mins ago
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Final Glance: Pharmaceuticals companies
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Will Bristol-Myers (BMY) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:45PM CDT
Bristol-Myers (BMY) is scheduled to release its first quarter 2014 results before the opening bell on Tuesday, Apr 29.
Midday Glance: Pharmaceuticals companies
AP - Mon Apr 28, 1:01PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
Early Glance: Pharmaceuticals companies
AP - Mon Apr 28, 9:56AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2014
M2 - Mon Apr 28, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b6657v/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - BioLineRx, Ltd. - Bayer AG - Alchemia Limited - Emisphere Technologies, Inc. - Merrion Pharmaceuticals Plc - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/b6657v/deep_vein
Global Alopecia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4ckzc5/alopecia) has announced the addition of the "Global Alopecia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Alopecia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Valeant Pharmaceuticals International, Inc. - Taisho Pharmaceutical Co., Ltd. - AntiCancer, Inc. - Panacea Biotec Limited - ProCertus BioPharm Inc. - AndroScience Corporation - Hygeia Therapeutics, Inc. - Kuhnil Pharmaceutical Co., Ltd. - Lee's Pharmaceutical Holdings Limited - Berg Pharma, LLC - vida therapeutics inc. Drug Profiles - abatacept - ruxolitinib - CB-0301 - calcitriol - Small Molecule Antagonists To Transforming Growth Factor Beta Receptor For Alopecia, Pulmonary Fibrosis And Dermatology - ZK-003 - HYG-430 - HYG-420 - HYG-410 - ASCJ-9 - KI-1104 - Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - V-2248 - ProDermaCel - Lipo-4MA - KI-1105 - Drug to Agonize P2Y5-Ligand LPA for Alopecia - Drug For Autoimmune Disorders - Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia - Peptide For Hair Regeneration For more information visit http://www.researchandmarkets.com/research/4ckzc5/alopecia
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - Mon Apr 28, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Say Hello to 3 Existing and Upcoming Next-Generation Blockbuster Drugs
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 12:26PM CDT
Investing in biopharmaceutical stocks can be an uphill battle from day one. For example, Medscape notes that of any 5,000 to 10,000 drugs investigated in a preclinical setting, only one will make it to pharmacy shelves . That's an extremely high...
Hepatitis C Space Heats Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 5:30PM CDT
What looked like a two-horse hepatitis C race between Gilead Sciences and AbbVie has gotten more interesting, with Merck and Bristol-Myers Squibb presenting data on their hepatitis C drugs at a scientific meeting earlier this month. ...
3 Questions About a Big Pharma Megamerger
Seth Robey, The Motley Fool - Motley Fool - Fri Apr 25, 1:30PM CDT
It's been hard to miss the action in Big Pharma this week, as some of the most established drug makers engaged in a series of acquisition, merger, and asset swap rumors. A buyout of English company AstraZeneca by American powerhouse Pfizer was...
Schedule for Upcoming Earnings Releases -- Research on Nokia, Boston Scientific, Merck & Co., and Bristol-Myers Squibb
PR Newswire - Fri Apr 25, 1:09PM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Nokia OYJ (NYSE: NOK), Boston Scientific Corp. (NYSE: BSX), Merck & Co. Inc. (NYSE: MRK) and Bristol-Myers Squibb Co. (NYSE: BMY). Full earnings notes on NOK, BSX, MRK and BMY can be downloaded upon signing up at:
